Concord Drugs Limited (CONCORD)

BSE: ₹80.41
Stock Performance
Corporate Announcements
No recent announcements available.

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 8.98 7.52 12.78 15.64 11.69 12.36 10.80 10.39 13.61 10.28 16.97 37.89
YOY Revenue Growth % - - - 27.11% 30.19% 64.44% -15.52% -33.57% 16.36% -16.86% 57.1% 264.6%
Other Income 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.02 0.01
Total Income 8.98 7.52 12.78 15.64 11.69 12.37 10.80 10.40 13.61 10.28 16.99 37.90
Total Expenses + 8.35 6.73 13.04 16.19 11.65 12.30 10.27 10.34 13.45 10.01 16.69 37.15
Cost of Materials Consumed 5.98 4.88 10.96 11.83 8.67 11.77 6.72 8.65 10.81 7.76 14.38 35.07
Employee Benefit Expense 1.38 1.46 1.54 1.69 1.46 0.93 1.00 1.24 0.89 1.09 1.24 1.75
Other Expenses 0.35 0.36 0.49 0.35 0.38 0.41 0.25 0.21 0.29 0.37 0.42 0.53
Operating Profit 0.64 0.79 -0.26 -0.55 0.04 0.06 0.53 0.05 0.16 0.27 0.28 0.74
OPM % 7.1% 10.5% -2% -3.5% 0.3% 0.5% 4.9% 0.5% 1.2% 2.6% 1.6% 1.9%
Profit Before Tax + 0.64 0.80 -0.26 -0.55 0.04 0.07 0.53 0.06 0.16 0.27 0.30 0.75
Tax Expense 0.14 0.24 -0.02 -0.21 0.01 0.02 0.30 0.02 0.04 0.08 0.08 0.22
Tax % 22.8% 29.6% - - 33.1% 34% 57% 32.8% 25.7% 29.1% 26.7% 29.4%
Profit After Tax 0.49 0.56 -0.24 -0.34 0.03 0.04 0.23 0.04 0.12 0.19 0.22 0.53
EPS (Basic) 0.53 0.60 -0.24 -0.34 0.03 0.04 0.23 0.04 0.12 0.31 0.16 0.47

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023
Revenue from Operations 78.74 45.24 44.92 52.08
YOY Revenue Growth % 74.02% 0.71% -13.74% -
Other Income 0.03 0.01 0.01 0.01
Total Income 78.77 45.26 44.93 52.09
Total Expenses + 77.30 44.57 44.30 50.84
Cost of Materials Consumed 68.03 35.81 33.66 41.16
Employee Benefit Expense 4.97 4.63 6.08 4.92
Other Expenses 1.60 1.25 1.55 1.58
Operating Profit 1.44 0.68 0.62 1.24
OPM % 1.8% 1.5% 1.4% 2.4%
Profit Before Exceptional 1.47 0.69 0.63 1.25
Exceptional Items 0.00 0.00 0.00 0.00
Profit Before Tax + 1.47 0.69 0.63 1.25
Tax Expense 0.42 0.36 0.16 0.26
Tax % 28.4% 51.4% 24.9% 21.1%
Profit After Tax 1.06 0.34 0.47 0.99
EPS (Basic) 0.95 0.34 0.47 1.06

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023
ASSETS
Non-Current Assets + 21.58 24.38 14.19 14.77
Property, Plant & Equipment 10.94 11.57 11.04 12.28
Capital Work in Progress 2.43 2.00 1.63 0.92
Non-Current Investments 0.78 0.80 0.84 0.00
Goodwill 0.00 0.00 0.00 0.00
Other Intangible Assets 0.00 0.00 0.00 0.00
Current Assets + 53.31 40.76 44.62 43.46
Inventories 25.52 25.27 22.92 20.06
Trade Receivables 24.38 13.60 19.83 15.81
Cash and Cash Equivalents 0.28 0.12 0.15 0.08
Current Investments 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity 48.51 34.11 33.82 31.70
Equity Share Capital 13.18 10.00 10.00 9.32
Other Equity 35.34 24.11 23.82 22.39
Non-Current Liabilities 5.31 4.85 3.65 4.91
Current Liabilities 21.07 26.18 21.34 21.61
Total Liabilities 26.37 31.03 24.99 26.53

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023
Cash from Operating Activities -6.77 3.72 0.79 1.66
Cash from Investing Activities -1.13 -2.32 -1.01 -2.27
Cash from Financing Activities 8.06 -1.43 0.28 0.62
Net Increase/Decrease in Cash 0.16 -0.02 0.07 0.02